New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
10:17 EDTEPD, GCI, JNPR, LFL, MMYT, RBC, TEVA, RIGOn The Fly: Analyst Upgrade Summary
Enterprise Products (EPD) upgraded to Outperform from Neutral at Credit Suisse... Gannett (GCI) upgraded to Equal Weight from Underweight at Barclays... Juniper (JNPR) upgraded to Outperform from Market Perform at Wells Fargo... LATAM Airlines (LFL) upgraded to Strong Buy from Outperform at Raymond James... MakeMyTrip (MMYT) upgraded to Outperform from Perform at Oppenheimer... Regal-Beloit (RBC) upgraded to Outperform from Neutral at RW Baird... Teva (TEVA) upgraded to Neutral from Sell at Goldman... Transocean (RIG) upgraded to Neutral from Sell at Citigroup.
News For EPD;GCI;JNPR;LFL;MMYT;RBC;TEVA;RIG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 10, 2014
07:47 EDTJNPRJuniper results could rebound in 2015, says Wells Fargo
After Juniper negatively preannounced its Q3 results, Wells Fargo thinks improved carrier spending, continued enterprise share gains and restructuring efforts could enable the company's results to improve in 2015. The firm cut its price target on the stock to $25-$27 from $28-$30. It keeps an Outperform rating on the shares.
07:27 EDTJNPRJuniper price target lowered to $27 from $29 at UBS
UBS lowered its price target on Juniper to $27 from $29 following the company's negative pre-announcement. The company cited lower than anticipated U.S. demand and UBS believes the downside earnings risk is limited by lower operating expenses and lower variable compensation. UBS maintains its Buy rating on Juniper.
07:20 EDTMMYTMakeMyTrip pullback creates buying opportunity, says Oppenheimer
Oppenheimer says yesterday's 10% pullback in shares of MakeMyTrip creates a buying opportunity. The firm believes the positive catalyst from the Online travel sector in India is in the "early innings." It reiterates an Outperform rating on MakeMyTrip with a $32 price target.
07:03 EDTJNPRJuniper price target lowered to $25 from $29.50 at Cantor
Cantor cut its price target on Juniper after the company lowered its Q3 guidance. However, the firm keeps a Buy rating on the shares.
October 9, 2014
18:47 EDTJNPROn The Fly: After Hours Movers
UP AFTER EARNINGS: Helen of Troy (HELE), up 3%... Barracuda Networks (CUDA), up marginally after reporting second quarter results. ALSO HIGHER: Sucampo Pharmaceuticals (SCMP), up 19.2% after announcing settlement agreement resolving patent litigation on AMITIZA... Civeo (CVEO), up 15% after Greenlight Capital reported a 9.99% stake in the company... EXCO Resources (XCO), up 10.6% after T. Boone Pickens says that company approached by buyers, reported by Bloomberg... EXACT Sciences (EXAS), up 3.7% after announcing final national coverage determination for Cologuard... US Ecology (ECOL), up 2.5% following announcement that it will replace Measurement Specialties (MEAS) in S&P 600. DOWN AFTER EARNINGS: Procera Networks (PKT), down 19.3%... Sizmek (SZMK), down 13.9% following third quarter revenue guidance... VOXX International (VOXX), down 12.5%... Knowles (KN), down 8.1% after lowering third quarter guidance... Microchip (MCHP), down 8.2% after lowering second quarter guidance... Juniper Networks (JNPR), down 3.6% after lowering third quarter outlook. ALSO LOWER: GT Advanced Technologies (GTAT), down 23.3% following a Bloomberg report that it will as to wind down sapphire operations.
16:20 EDTJNPRJuniper down 5% after lowering Q3 outlook
16:17 EDTJNPRJuniper reports preliminary Q3 adjusted EPS 34c-36c, consensus 38c
Subscribe for More Information
16:11 EDTTEVAAlexza reports 32,278 Adasuve units shipped to Teva in Q3
Subscribe for More Information
15:46 EDTMMYTMakeMyTrip volatility increases on wide share price movement
MakeMyTrip October put option implied volatility is at 71, November is a 65, February is at 61; compared to its 26-week average of 54 according to Track Data, suggesting large price movement.
15:40 EDTMMYTMakeMyTrip quickly drops over 15% to $22.67
Subscribe for More Information
11:37 EDTRIGStocks with call strike movement; RIG APC
Transocean (RIG) January 34 call option implied volatility increased 5% to 38, Anadarko (APC) January 115 call option implied volatility increased 8% to 39 according to IVolatility.
10:00 EDTRIGOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Acuity Brands (AYI) upgraded at Oppenheimer... Agnico-Eagle (AEM) upgraded to Buy from Hold at Desjardins... Apple (AAPL) upgraded to Outperform from Perform at Oppenheimer... Bank of Montreal (BMO) upgraded to Buy from Hold at Canaccord... Basic Energy (BAS) upgraded to Hold from Underperform at Jefferies... BreitBurn Energy (BBEP) upgraded to Outperform from Perform at Oppenheimer... Golden Minerals (AUMN) upgraded at Roth Capital... Helmerich & Payne (HP) upgraded to Buy from Hold at Jefferies... II-VI (IIVI) upgraded to Buy from Neutral at DA Davidson... LivePerson (LPSN) upgraded at Credit Suisse... Luminex (LMNX) upgraded to Market Perform at Cowen... MGM Resorts (MGM) upgraded at Craig-Hallum... New Gold (NGD) upgraded to Buy from Hold at Desjardins... New Source Energy (NSLP) upgraded to Outperform from Perform at Oppenheimer... Pacific Coast Oil (ROYT) upgraded to Buy from Hold at Stifel... Pioneer Energy (PES) upgraded to Buy from Hold at Jefferies... Precision Drilling (PDS) upgraded to Strong Buy from Outperform at Raymond James... Randgold (GOLD) upgraded to Overweight from Neutral at HSBC... Resource Capital (RSO) upgraded to Buy from Hold at MLV & Co.... Toyota (TM) upgraded to Buy from Neutral at BofA/Merrill... Transocean (RIG) upgraded to Outperform from Sector Perform at Iberia... Universal Technical (UTI) upgraded to Outperform from Market Perform at Wells Fargo... Vulcan Materials (VMC) upgraded to Buy from Neutral at Longbow.
06:26 EDTRIGTransocean upgraded to Outperform from Sector Perform at Iberia
October 8, 2014
10:00 EDTJNPROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:05 EDTTEVATeva initiates NDA submission to FDA for CEP-33237
Teva Pharmaceutical announced the initiation of a rolling New Drug Application submission to the U.S. Food and Drug Administration for hydrocodone bitartrate extended-release tablets designed with Teva’s proprietary technology providing potential abuse-deterrent properties CEP-33237 as allowed for fast track designated products. Teva expects to complete the NDA submission by the end of 2014. Teva also announced positive results from a nasal Human Abuse Liability study which supports the NDA. The nasal HAL study found that in nondependent, recreational opioid users, abuse potential for crushed intranasal CEP-33237 was significantly lower than intranasal immediate-release hydrocodone. Teva has now completed positive HAL studies in the two most common routes of hydrocodone abuse, oral and intranasal. CEP-33237 demonstrated a safety profile in the Phase III study that is consistent with the known safety profile of hydrocodone and other opioid analgesic therapies. Adverse events reported in 5% or more of hydrocodone-treated patients during either the titration or double-blind treatment periods included nausea, constipation, vomiting, headache, somnolence and dizziness.
07:38 EDTJNPRJuniper downgraded at MKM Partners
Subscribe for More Information
07:32 EDTJNPRJuniper downgraded at MKM Partners
As noted earlier, MKM Partners downgraded Juniper to Neutral from Buy. The firm thinks that the bull case on the stock is too centered on cost cuts and low valuation, and not enough on the company's growth outlook. MM Partners also believes that the service provider router market faces numerous overhangs. Target $24.
07:10 EDTJNPRJuniper downgraded to Neutral from Buy at MKM Partners
Subscribe for More Information
06:47 EDTTEVALawmakers may push for new regulations on generic drug makers, NY Times says
After the prices of some generic drugs soared more than 1,000% over the last year, two influential members of Congress are probing the sector and threatening to look to impose new regulations on it, according to The New York Times. Generic drug makers include Teva (TEVA), Mylan (MYL), Actavis (ACT), and Lannett (LCI).Reference Link
October 7, 2014
08:18 EDTJNPRJuniper execution could drive 40% upside, says Bernstein
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use